文献速递慢性静脉疾病

使用Clarivein装置机械化学消融治疗大隐静脉功能不全的长期结局

Long-term outcomes of mechanochemical ablation using the Clarivein device for the treatment of great saphenous vein incompetence.
PubMed 文献 · J Vasc Surg Venous Lymphat Disord · 2024-09-11

本研究为单中心前瞻性队列研究,随访多中心随机对照试验中使用Clarivein联合液体聚多卡醇治疗大隐静脉功能不全的患者,平均随访8.4±0.9年。解剖成功率为60.5%,无返流解剖成功率为72.8%。尽管解剖成功率下降,临床评分和疾病特异性生活质量较基线仍显著改善。

要点

  • 平均随访8.4±0.9年,解剖成功率为60.5%,无返流解剖成功率为72.8%。
  • 总体VCSS从5.3±2.4改善至4.1±2.4,DAVVQ从13.5改善至10.5(P<.001)。
  • VCSS和DAVVQ改善仅在解剖成功患者中显著,未成功者无显著改善。

核心结论

  • 随访超过8年,Clarivein治疗大隐静脉功能不全的解剖成功率降至60.5%,但临床评分和疾病特异性生活质量较基线仍显著改善。
  • 无 convincing 证据表明无返流与临床和生活质量结局的相关性优于不考虑返流的再通。

研究设计与样本

  • 单中心前瞻性队列研究,随访多中心随机对照试验中使用Clarivein联合液体聚多卡醇治疗大隐静脉功能不全的患者。
  • 共纳入109例患者(115条肢体),平均随访8.4±0.9年(范围5.5-10.3年)。

主要发现

  • 解剖成功率为60.5%,无返流解剖成功率为72.8%。
  • 总体平均VCSS从基线5.3±2.4改善至4.1±2.4,总体DAVVQ中位数从13.5(IQR 8.7-20.0)改善至10.5(IQR 5.3-16.2)(P<.001)。
  • 达到解剖成功者VCSS从5.5±2.7改善至3.7±2.5(P<.001),未达到者从5.0±1.7至4.5±1.9(P=.20)。
  • 达到解剖成功者DAVVQ从13.5(IQR 8.7-20.6)改善至10.3(IQR 3.0-14.5)(P<.01),未达到者从12.9(IQR 8.3-19.3)至10.8(IQR 6.7-18.2)(P=.35)。
  • SF-36总体评分中,活力、心理健康和总体健康领域显著恶化。

关键数值与推荐

  • 解剖成功定义为完全闭塞或再通段长度<10 cm,不考虑返流。
  • 无返流解剖成功定义为完全闭塞或再通段伴返流长度<10 cm。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: The short-term anatomical success rates of mechanochemical ablation using the Clarivein device (Merit Medical) in the treatment of great saphenous vein (GSV) incompetence are high. However, the anatomical success rates seem to drop over time. The aim of this study was to determine the long-term outcomes of GSV treatment using the Clarivein and to assess whether specific anatomical features better correlate with clinical or quality of life (QoL)-related outcomes. METHODS: This is a single-center, prospective cohort study in follow-up of a multicenter, randomized controlled trial using Clarivein with liquid polidocanol for the treatment of GSV incompetence. The primary outcome was anatomical success (AS), defined as complete occlusion or a recanalized segment, irrespective of reflux, of <10 cm in length. In addition, reflux-free anatomical success (RF-AS) was determined, and defined as complete occlusion or a recanalized segment with <10 cm of reflux. Clinical success was assessed using the Venous Clinical Severity Score (VCSS), and QoL was assessed using the Dutch version of the Aberdeen Varicose Vein Questionnaire (DAVVQ) and the 36-Item Short Form Health Survey (SF-36). Subgroup analyses were performed based on whether AS or RF-AS was achieved or not. RESULTS: A total of 109 patients (115 limbs) were included. The mean follow-up time was 8.4 ± 0.9 years (range, 5.5-10.3 years). AS was seen in 60.5% of limbs, and RF-AS was seen in 72.8% of limbs. Compared with baseline, the overall mean VCSS improved from 5.3 ± 2.4 to 4.1 ± 2.4, and the overall median DAVVQ score from 13.5 (interquartile range [IQR], 8.7-20.0) to 10.5 (IQR, 5.3-16.2) (P < .001). Improvement in VCSS was only significant in patients with successful treatment: from 5.5 ± 2.7 to 3.7 ± 2.5 (P < .001) if AS was achieved and from 5.0 ± 1.7 to 4.5 ± 1.9 (P = .20) if AS was not achieved. The same results were found for DAVVQ scores: improvement from13.5 (IQR, 8.7-20.6) to 10.3 (IQR, 3.0-14.5) (P < .01) if AS was achieved and from 12.9 (IQR, 8.3-19.3) to 10.8 (IQR, 6.7-18.2) (P = .35) if AS was not achieved. Regarding the overall SF-36 scores, the domains of vitality, mental health, and general health worsened significantly. CONCLUSIONS: In over 8 years of follow-up, the anatomical success rate after the treatment of GSV incompetence using the Clarivein device decreased to 60.5%. However, clinical scores and disease-specific QoL still improved significantly compared with baseline. We found no convincing evidence that the absence of reflux correlates better with clinical and QoL-related outcomes compared with recanalization irrespective of reflux.

来源:J Vasc Surg Venous Lymphat Disord,查看原文。版权归原作者所有。

引用

  1. Oud S, Alozai T, Lam YL, et al. Long-term outcomes of mechanochemical ablation using the Clarivein device for the treatment of great saphenous vein incompetence. J Vasc Surg Venous Lymphat Disord. 2024. PMID: 39270843. doi:10.1016/j.jvsv.2024.101967

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。